Kathryn Penkus Corzo

Kathryn Penkus Corzo has a diverse and extensive work experience in the biopharmaceutical industry. Kathryn is currently serving as the Chief Operating Officer at bit.bio since November 2021. Prior to this, they held the position of Head of Development Oncology Cell Therapies at Takeda from February 2020 to October 2021.

Kathryn also served as a Member of the Board of Directors at Maverick Therapeutics from October 2020 to March 2021. Before joining Takeda, they worked at Sanofi for several years in various leadership roles. Kathryn was the Head of the North American Innovation Center and R&D Digital Accelerator from October 2019 to February 2020. Prior to that, they held the position of VP, R&D Global Program Head for Isatuximab (aCD38mAb) from January 2015 to September 2019, where they successfully led the global integrated development strategy from pre-POC to BLA filing and approval.

Kathryn also served as the AVP, Global Project Leader Oncology-CD38 Program from January 2012 to January 2015 and as the AVP, Global Development Operations & Strategic Planning from September 2010 to September 2013 at Sanofi.

Earlier in their career, they worked at Syndax Pharmaceuticals as part of the Clinical Development & Medical Communication team from May 2008 to September 2010. Prior to that, they had a significant tenure at Eli Lilly and Company, where they held various leadership responsibilities in the Oncology Business Unit from September 1996 to June 2008.

Kathryn started their career at Roche in 1989, where they held the positions of Global Product Manager from January 1992 to December 1994 and Market Manager, Pharma International from June 1989 to December 1991.

Overall, Kathryn Penkus Corzo has demonstrated a strong track record of leadership and expertise in the biopharmaceutical industry, with a focus on oncology and innovative therapies.

Kathryn Penkus Corzo obtained their BSC Pharm degree in Pharmacy from Massachusetts College of Pharmacy and Health Sciences from 1979 to 1984. Later, they pursued an Executive Master of Business Administration (MBA) from MIT Sloan School of Management, completing it from 2017 to 2019.